Clinical trials: Severe Community-Acquired Pneumonia
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Community Acquired Pneumonia., Acute Hypoxemic Respiratory Failure
Efects of Noninvasive Mechanical Ventilation and Conventional Mechanical Ventilation in Patients With Severe Comunity Pneumonia
The purpose of this study is to determine whether the noninvasive ventilation is more effective in the treatment of severe comunity acquired pneumonia in comparison with the conventional mechanical ventilation with orotracheal…
- Trial name
- NIMV AND SCAP (NCT00523497)
- Testing
- Non invasive mechanical ventilation
- Where
- Argentina
- Sponsor
- Hospital Privado del Sur
Severe Communtity-Acquired Pneumonia
Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia
Patients with severe community-acquired pneumonia are included Half of the patients are treated with a 3 day course of intravenous antibiotics, followed, when clinical stable, by a course of oral antibiotics.
- Trial name
- NCT00273676
- Testing
- Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- UMC Utrecht
Community-acquired Pneumonia
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
To assess the effectiveness of a management strategy combining a broad panel respiratory mPCR and an algorithm of early antibiotic de-escalation and discontinuation based on both the mPCR results and the procalcitonin…
- Trial name
- MULTI-CAP (NCT03452826)
- Testing
- Antibiotic therapy according to the result of mPCR (device)
- Where
- France
- Volunteers
- 411 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumonia, Bacterial
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
- Trial name
- NCT00538694
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Severe Acute Respiratory Infection, Community-acquired Pneumonia
mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients
Severe Community-acquired pneumonia (SCAP) is a leading global infectious cause of intensive care unit (ICU) admission (approximately 20%-30%), and the primary reason of mortality and morbidity in immunocompromised patients.
- Conditions
- Severe Acute Respiratory Infection, Community-acquired Pneumonia, Respiratory Tract Infections, Pneumonia
- Trial name
- MATESHIP (NCT05290454)
- Testing
- mNGS-guided treatment
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Qilu Hospital of Shandong University
Community Acquired Pneumonia, Respiration Failure
A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia
Severe community acquired pneumonia is common and associated with high mortality. Conventional microbiological diagnostics identify pathogens in approximately half of cases, which is inadequate for both clinical and…
- Conditions
- Community Acquired Pneumonia, Respiration Failure, Pneumonia
- Trial name
- S-CAP (NCT02963142)
- Where
- United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Adenovirus Infections, Human
Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults
Severe community-acquired pneumonia caused by adenovirus (hereafter referred to as severe adenovirus pneumonia) is one of the common forms of severe community-acquired pneumonia in immunocompetent adults.
- Trial name
- CAPSTONE-AD (NCT07152600)
- Testing
- Saline (0.9%, sterile, for infusion), low dose Methylprednisolone, Moderate dose Methylprednisolone
- Volunteers
- 262 people
- Sponsor
- Qingyuan Zhan
Community-acquired Pneumonia, Covid19
Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia
Respiratory infection with the SARS-CoV2 virus is associated with a major risk of viral pneumonia that can lead to respiratory distress requiring resuscitation.
- Trial name
- LPSARS2 (NCT04505605)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
Community Acquired Pneumonia, Severe
Ticagrelor in Severe Community Acquired Pneumonia
The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia.
- Trial name
- TCAP (NCT01998399)
- Testing
- Ticagrelor
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gordon Bernard
Pneumonia
A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia
The purpose of this study is to evaluate the effectiveness and safety of two antibiotic regimens in the treatment of community-acquired pneumonia in non-hospitalized adult patients.
- Trial name
- NCT00236821
- Testing
- levofloxacin
- Volunteers
- 530 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Community Acquired Pneumonia
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
The purpose of this study is to prove the clinical and bacteriological non-inferiority of ampicillin/amoxicillin versus moxifloxacin in hospitalized patients with non-severe community-acquired pneumonia.
- Trial name
- PENCAP (NCT00887276)
- Testing
- Moxifloxacin, Ampicillin;Amoxicillin
- Where
- 8 sites in Germany
- Volunteers
- 290 people
- Sponsor
- University of Ulm
Pneumonia, Child
Predicting Severe Outcomes Among Children Hospitalized With Community-acquired Pneumonia
In this study, investigators aimed to develop and validate a risk score to predict severe outcomes (e.g., mortality and ICU admission) in children who were admitted to the Children's Hospital of Fudan University between 2017 and…
- Conditions
- Pneumonia, Child, Prognosis
- Trial name
- NCT05744609
- Testing
- exposures of interest: epidemiological data, clinical characteristics, laboratory data, and chest radiographic reports
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Children's Hospital of Fudan University
Community-acquired Pneumonia
MACCE in Hospitalized Patients With Community-acquired Pneumonia
Community-acquired pneumonia is the most common infection leading to hospitalization in intensive care units and the most common cause of death associated with infection disease.
- Trial name
- NCT01773863
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Roma La Sapienza
Community-acquired Pneumonia
Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia
The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
- Trial name
- BICAP (NCT00818610)
- Testing
- Beta lactam (amoxicillin / clav. acid OR cefuroxime), Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
- Where
- 6 sites in Switzerland
- Volunteers
- 601 people
- Sponsor
- Swiss National Fund for Scientific Research